Výsledky vyhledávání - "PierGiorgio, Cojutti"

A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol

Autor: Pierluigi Viale, Paolo Gaibani, Maddalena Giannella, Federico Pea, Piergiorgio Cojutti, Milo Gatti, Michele Bartoletti, Matteo Conti

Publikováno v: Journal of Global Antimicrobial Resistance, Vol 27, Iss, Pp 294-298 (2021)

Objectives: The aim of this study was to explore the relationship between cefiderocol pharmacokinetic/pharmacodynamic (PK/PD) target attainment and microbiological outcome in critically ill patients affected by extensively drug-resistant Acinetobacte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f89b48c072318886f99f9ea3a9bd8a7
http://www.sciencedirect.com/science/article/pii/S2213716521002290

Zobrazit plný text záznamu

A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study

Autor: Ezio, Zanon, Samantha, Pasca, Gianluca, Sottilotta, Angelo C, Molinari, Antonietta, Ferretti, Patrizia, Di Gregorio, Berardino, Pollio, Michele, Pizzuti, Lucia Dora, Notarangelo, Chiara, Biasoli, Piergiorgio, Cojutti, Federico, Pea, Paolo, Simioni, Flora, Peyvandi

Publikováno v: Blood transfusion = Trasfusione del sangue.

Congenital factor XIII (FXIII) deficiency is a rare coagulation disorder characterized by muscular or mucocutaneous bleeding with life-threatening intracranial hemorrhages (ICHs), especially in cases with severe disease. The best treatment is the use

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b9eb70b133a7e438c4d4b981785ca415
https://pubmed.ncbi.nlm.nih.gov/36580025

Zobrazit plný text záznamu

Akademický článek

Monitoring polypharmacy in healthcare systems through a multi-setting survey: should we put more attention on long term care facilities?

Autor: Luca Arnoldo, Giovanni Cattani, Piergiorgio Cojutti, Federico Pea, Silvio Brusaferro

Publikováno v: Journal of Public Health Research, Vol 5, Iss 3 (2016)

Background. Polypharmacy is a main issue of patient safety in all healthcare settings (i.e. increase adverse drug reactions and incidence of drug-drug interactions, etc.). The main object of the study was to evaluate the prevalence of polypharmacy an

Externí odkaz: https://doaj.org/article/1da6f2cdff19416f82d5e0016f4ecacc

Zobrazit plný text záznamu

Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round/A Case Study

Autor: Federico Pea, Piergiorgio Cojutti, Assunta Sartor, Silvia Mattelig, Alessia Carnelutti

Publikováno v: Therapeutic Drug Monitoring. 42:349-352

The authors present the case of a critically ill morbidly obese patient (body mass index, 51.2 kg/m) who suffered from methicillin-resistant Staphylococcus epidermidis, and Candida albicans bloodstream infections. Initial treatment with caspofungin a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7367655caa2ce478b2a146cdea712c6
https://doi.org/10.1097/ftd.0000000000000740

Zobrazit plný text záznamu

Reply to Baklouti et al., 'Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?'

Autor: Federico Pea, Sara K. Tedeschi, Pierluigi Viale, Matteo Conti, Piergiorgio Cojutti, Matteo Rinaldi, Eleonora Zamparini, Nicolò Rossi

Publikováno v: Antimicrob Agents Chemother

We thank Baklouti et al. (1) for commenting on our population pharmacokinetic study of dalbavancin for optimal treatment of adult patients with staphylococcal osteoarticular infections (2) and for suggesting that our model tends to underestimate the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb798107f48a167efda403a46f54d6c0
https://doi.org/10.1128/aac.01908-21

Zobrazit plný text záznamu

Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa

Autor: Giulia Schillani, Piergiorgio Cojutti, Natalia Maximova, Federico Pea, William W. Hope

Publikováno v: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OBJECTIVES: To conduct a population pharmacokinetic analysis of continuous-infusion ceftazidime in a retrospective cohort of paediatric HSCT patients who were empirically treated for febrile neutropenia (FN) and who underwent therapeutic drug monitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e2fdb313ce89578c4c6fabee9cd4b9
https://doi.org/10.1093/jac/dkz065

Zobrazit plný text záznamu

Population Pharmacokinetics of Dalbavancin and Dosing Consideration for Optimal Treatment of Adult Patients with Staphylococcal Osteoarticular Infections

Autor: Nicolò Rossi, Matteo Rinaldi, Eleonora Zamparini, Piergiorgio Cojutti, Sara K. Tedeschi, Pierluigi Viale, Matteo Conti, Federico Pea

Publikováno v: Antimicrob Agents Chemother

Dalbavancin is gaining interest in the treatment of complex osteoarticular (OA) infections. We aimed to conduct a population pharmacokinetic analysis of dalbavancin in a prospective cohort of adult patients with OA infections caused by Gram-positive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc02a410cab65ce22a118957ba3716e1
https://europepmc.org/articles/PMC8092885/

Zobrazit plný text záznamu

Akademický článek

The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTOR^TM2 trial to a real-world study: a head-to-head comparison.

Autor: Pasca, Samantha, PierGiorgio, Cojutti, Pea, Federico

Publikováno v: Journal of Thrombosis & Thrombolysis; Nov2022, Vol. 54 Issue 4, p593-596, 4p

Zobrazit plný text záznamu

Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections

Autor: Maddalena Giannella, Federico Pea, Pierluigi Viale, Antonio Siniscalchi, Renato Pascale, Alessio Dell'Olio, Milo Gatti, Piergiorgio Cojutti, Cristiana Laici, Tommaso Tonetti

Publikováno v: Antibiotics
Volume 10
Issue 11
Antibiotics, Vol 10, Iss 1311, p 1311 (2021)

Background: Emerging data suggest that more aggressive beta-lactam PK/PD targets could minimize the occurrence of microbiological failure and/or resistance development. This study aims to assess whether a PK/PD target threshold of continuous infusion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca62a97816891026927cc1b51ee603e3
http://hdl.handle.net/11585/841324

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání